|
|
|
Back to Symposia overview
EMERGING THERAPIES IN TYPE 1 DIABETES:
CAN WE PRESERVE THE BETA-CELL?
Monday, 20 September 2010, 14:30 – 17:00
Sanger Hall
| Chair: |
Johnny Ludvigsson, SE |
|
| 14:30 – 14:35 |
Welcome and introduction
Johnny Ludvigsson, SE |
|
| Current challenges in clinical practice: reducing the impact of type 1 diabetes |
|
| 14:35 – 15:05 |
Addressing the burden of type 1 diabetes
Andrew Morris, UK |
|
| 15:05 – 15:35 |
Highs and lows of type 1 diabetes
Stephanie Amiel, UK |
|
| Immune-based therapeutic approaches for treating type 1 diabetes |
|
| 15:35 – 16:10 |
Immune pathways and novel therapeutic targets
Mark Peakman, UK |
|
| 16:10 – 16:40 |
Preserving the beta-cell: advances in monoclonal antibody therapy
Bart Keymeulen, BE |
|
| 16:40 – 17:00 |
Panel discussion
All |
|
For further information please contact:
Dr. Phil Ambery
GlaxoSmithKline
New Frontiers Science Park South – H83/3316
The Pinnacles
Third Avenue
Harlow
Essex, CM19 5AW
UK
Tel: +44 (0)1279 644330
Fax: +44 (0)1279 644976
E-mail: phil.d.ambery@gsk.com
Website: www.gsk.com
|
 |
|
|
© 2010 EASD | Contact | Imprint
